Resveratrol attenuates norepinephrine-induced ovarian cancer invasiveness through downregulating hTERT expression
- 439 Downloads
Stress hormone norepinephrine (NE) has been associated with acquisition of cancer progression, and naturally occurring phytoalexin resveratrol (REV) has been known to suppress cancer growth and progression. In the present study, we determine the effect of REV on NE-induced ovarian cancer invasiveness. Pretreatment of REV significantly inhibited NE-induced ovarian cancer cell epithelial-to-mesenchymal transition with concomitant recovery of E-cadherin expression. In addition, our data showed that REV downregulates NE-induced human telomerase reverse transcriptase (hTERT) expression through inhibiting Src phosphorylation and HIF-1α expression. Further, REV reduced NE-induced Slug expression and subsequent ovarian cancer invasion. More importantly, combined treatment of REV with a pharmacological inhibitor of beta adrenergic receptor significantly attenuated NE-induced ovarian cancer invasion compared to single treatment. Therefore, we demonstrate interference of a Src and HIF-1α/hTERT/Slug signaling cascade by REV, providing potential therapeutic targets and inhibition of ovarian cancer.
KeywordsResveratrol Telomerase Ovarian cancer Metastasis
This study was supported by a Grant from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2014R1A2A1A01004363, NRF-2013R1A1A2A10059565, NRF-2014R1A2A1A11051091).
Compliance with ethical standards
Conflict of Interest
The authors disclose no potential conflicts of interest.
- Armaiz-Pena, G.N., J.K. Allen, A. Cruz, R.L. Stone, A.M. Nick, Y.G. Lin, L.Y. Han, L.S. Mangala, G.J. Villares, P. Vivas-Mejia, C. Rodriguez-Aguayo, A.S. Nagaraja, K.M. Gharpure, Z. Wu, R.D. English, K.V. Soman, M.M. Shazhad, M. Zigler, M.T. Deavers, A. Zien, T.G. Soldatos, D.B. Jackson, J.E. Wiktorowicz, M. Torres-Lugo, T. Young, K. De Geest, G.E. Gallick, M. Bar-Eli, G. Lopez-Berestein, S.W. Cole, G.E. Lopez, S.K. Lutgendorf, and A.K. Sood. 2013. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Nature Communications 4: 1403.CrossRefPubMedPubMedCentralGoogle Scholar
- Hassan, S., Y. Karpova, D. Baiz, D. Yancey, A. Pullikuth, A. Flores, T. Register, J.M. Cline, R. D’Agostino Jr, N. Danial, S.R. Datta, and G. Kulik. 2013. Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation 123: 874–886.PubMedPubMedCentralGoogle Scholar
- Hu, F.W., L.L. Tsai, C.H. Yu, P.N. Chen, M.Y. Chou, and C.C. Yu. 2012. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Molecular Nutrition & Food Research 56: 1247–1258.CrossRefGoogle Scholar
- Kotha, A., M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A.S. Zervos, B. Carter, J. Turkson, and R. Jove. 2006. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Molecular Cancer Therapeutics 5: 621–629.CrossRefPubMedGoogle Scholar
- Lang, K., T.L. Drell, A. Lindecke, B. Niggemann, C. Kaltschmidt, K.S. Zaenker, and F. Entschladen. 2004. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. International Journal of Cancer 112: 231–238.CrossRefPubMedGoogle Scholar
- Lanzilli, G., M.P. Fuggetta, M. Tricarico, A. Cottarelli, A. Serafino, R. Falchetti, G. Ravagnan, M. Turriziani, R. Adamo, O. Franzese, and E. Bonmassar. 2006. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. International Journal of Oncology 28: 641–648.PubMedGoogle Scholar
- Lara, H.E., M. Dorfman, M. Venegas, S.M. Luza, S.L. Luna, A. Mayerhofer, M.A. Guimaraes, E.S.A.A. Rosa, and V.D. Ramirez. 2002. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. Microscopy Research and Technique 59: 495–502.CrossRefPubMedGoogle Scholar
- Lutgendorf, S.K., S. Cole, E. Costanzo, S. Bradley, J. Coffin, S. Jabbari, K. Rainwater, J.M. Ritchie, M. Yang, and A.K. Sood. 2003. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clinical Cancer Research 9: 4514–4521.PubMedGoogle Scholar
- Nilsson, M.B., G. Armaiz-Pena, R. Takahashi, Y.G. Lin, J. Trevino, Y. Li, N. Jennings, J. Arevalo, S.K. Lutgendorf, G.E. Gallick, A.M. Sanguino, G. Lopez-Berestein, S.W. Cole, and A.K. Sood. 2007. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. Journal of Biological Chemistry 282: 29919–29926.CrossRefPubMedGoogle Scholar
- Palm, D., K. Lang, B. Niggemann, T.L. Drell, K. Masur, K.S. Zaenker, and F. Entschladen. 2006. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. International Journal of Cancer 118: 2744–2749.CrossRefPubMedGoogle Scholar
- Park, S.Y., J.H. Kang, K.J. Jeong, J. Lee, J.W. Han, W.S. Choi, Y.K. Kim, J. Kang, C.G. Park, and H.Y. Lee. 2011. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. International Journal of Cancer 128: 2306–2316.CrossRefPubMedGoogle Scholar
- Shahzad, M.M., J.M. Arevalo, G.N. Armaiz-Pena, C. Lu, R.L. Stone, M. Moreno-Smith, M. Nishimura, J.W. Lee, N.B. Jennings, J. Bottsford-Miller, P. Vivas-Mejia, S.K. Lutgendorf, G. Lopez-Berestein, M. Bar-Eli, S.W. Cole, and A.K. Sood. 2010. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. Journal of Biological Chemistry 285: 35462–35470.CrossRefPubMedGoogle Scholar
- Siegel, R., C. Desantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, D. Cooper, T. Gansler, C. Lerro, S. Fedewa, C. Lin, C. Leach, R.S. Cannady, H. Cho, S. Scoppa, M. Hachey, R. Kirch, A. Jemal, and E. Ward. 2012. Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians 62: 220–241.Google Scholar
- Thaker, P.H., L.Y. Han, A.A. Kamat, J.M. Arevalo, R. Takahashi, C. Lu, N.B. Jennings, G. Armaiz-Pena, J.A. Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, L.S. Mangala, T.J. Kim, R.L. Coleman, C.N. Landen, Y. Li, E. Felix, A.M. Sanguino, R.A. Newman, M. Lloyd, D.M. Gershenson, V. Kundra, G. Lopez-Berestein, S.K. Lutgendorf, S.W. Cole, and A.K. Sood. 2006. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine 12: 939–944.CrossRefPubMedGoogle Scholar
- Xia, L., X.X. Wang, X.S. Hu, X.G. Guo, Y.P. Shang, H.J. Chen, C.L. Zeng, F.R. Zhang, and J.Z. Chen. 2008. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. British Journal of Pharmacology 155: 387–394.CrossRefPubMedPubMedCentralGoogle Scholar
- Zhang, Q., X. Tang, Q.Y. Lu, Z.F. Zhang, J. Brown, and A.D. Le. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapeutics 4: 1465–1474.CrossRefPubMedGoogle Scholar